Atopic dermatitis (AD) is a pruritic, chronic or chronically relapsing, highly symptomatic inflammatory skin disease characterized by excessive T cell activation leading to significant skin infiltration by T cells and dendritic cells (Bieber 2010). Presentation is varied, but includes skin manifestations and pruritus, with associated sleep disturbances and subsequent skin infections. The course of disease includes relapses of varying duration and severity.
The purpose for this extension is to allow patients the opportunity to continue to receive baricitinib while allowing clinicians and patients freedom to use a low potency TCS product/dosing form (e.g., cream, ointment) that is preferred and is available as part of local standard of care.